The association between erythema nodosum and pyoderma gangrenosum and pediatric inflammatory bowel disease.

Autor: Yousif ML; College of Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, USA., Ritchey A; Department of Biostatistics, Phoenix Children's Hospital, Phoenix, Arizona, USA., Mirea L; Department of Biostatistics, Phoenix Children's Hospital, Phoenix, Arizona, USA., Patel AS; Department of Gastroenterology, Phoenix Children's Hospital, Phoenix, Arizona, USA., Price H; College of Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, USA.; Phoenix Children's Hospital, Phoenix, Arizona, USA., O'Haver J; Department of Dermatology, Phoenix Children's Hospital, Phoenix, Arizona, USA., Rudo-Stern J; College of Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, USA.; Department of Gastroenterology, Phoenix Children's Hospital, Phoenix, Arizona, USA., Montoya L; Department of Dermatology, Phoenix Children's Hospital, Phoenix, Arizona, USA., Gonzalez-Llanos L; Phoenix Children's Hospital, Phoenix, Arizona, USA., Smith J; Department of Gastroenterology, Phoenix Children's Hospital, Phoenix, Arizona, USA., Zeblisky K; Phoenix Children's Hospital, Phoenix, Arizona, USA., Pasternak B; Department of Gastroenterology, Phoenix Children's Hospital, Phoenix, Arizona, USA.
Jazyk: angličtina
Zdroj: Journal of pediatric gastroenterology and nutrition [J Pediatr Gastroenterol Nutr] 2024 Nov; Vol. 79 (5), pp. 1009-1016. Date of Electronic Publication: 2024 Sep 09.
DOI: 10.1002/jpn3.12370
Abstrakt: Objectives: The objectives of this study is to estimate rates and identify factors associated with erythema nodosum (EN) and pyoderma gangrenosum (PG) in pediatric patients with inflammatory bowel disease (IBD).
Methods: This cohort study examined longitudinal visits of patients aged ≤ 21 years from the ImproveCareNow (ICN) registry. We evaluated the association of factors at the patient-level (demographics and IBD diagnosis age) and visit-level (IBD severity scores, markers and phenotypes, comorbidities, and treatment) with the presence of EN and PG, using longitudinal logistic regression models adjusted for time and within-patient clustering.
Results: A total of 285,913 visits from 32,497 patients aged ≤ 21 years from the ICN registry were analyzed. The occurrence of EN was 1.57% (95% confidence interval [95% CI]: 1.43%-1.71%) and the occurrence of PG was 0.90% (95% CI: 0.80%-1.00%). Co-occurrence of EN and PG was reported in 0.30% (95% CI: 0.25%-0.37%) patients. Both EN and PG were associated (p < 0.0001) with worse intestinal disease, lower remission, higher inflammatory markers, and extraintestinal manifestations (EIMs) arthritis and uveitis.
Conclusions: EN and PG were associated with increased disease severity and other noncutaneous EIMs (arthritis and uveitis). A small subset of patients had developed both EN and PG.
(© 2024 European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.)
Databáze: MEDLINE
Externí odkaz: